Allergan CEO David Pyott recently let it known the company’s intention to divest its LAP-Band business. In this interview, he details the decision and the strong market metrics behind Allergan’s strategy to move away from the business.
Allergan CEO details decision to exit LAP-Band businessPrevious post: Boston Scientific CEO bares his soul, talks J&J transition Next post: FDA approves the first bionic eye by Second Sight |
